Dry powder inhalers in COPD, lung inflammation and pulmonary infections

Priya Muralidharan, Don Hayes, Heidi M. Mansour

Research output: Contribution to journalReview articlepeer-review

62 Scopus citations


Introduction: The number of pulmonary diseases that are effectively treated by aerosolized medicine continues to grow.Areas covered: These diseases include chronic obstructive pulmonary disease (COPD), lung inflammatory diseases (e.g., asthma) and pulmonary infections. Dry powder inhalers (DPIs) exhibit many unique advantages that have contributed to the incredible growth in the number of DPI pharmaceutical products. To improve the performance, there are a relatively large number of DPI devices available for different inhalable powder formulations. The relationship between formulation and inhaler device features on performance of the drug-device combination product is critical. Aerosol medicine products are drug-device combination products. Device design and compatibility with the formulation are key drug-device combination product aspects in delivering drugs to the lungs as inhaled powders. In addition to discussing pulmonary diseases, this review discusses DPI devices, respirable powder formulation and their interactions in the context of currently marketed DPI products used in the treatment of COPD, asthma and pulmonary infections.Expert opinion: There is a growing line of product options available for patients in choosing inhalers for treatment of respiratory diseases. Looking ahead, combining nanotechnology with optimized DPI formulation and enhancing device design presents a promising future for DPI development.

Original languageEnglish (US)
Pages (from-to)947-962
Number of pages16
JournalExpert Opinion on Drug Delivery
Issue number6
StatePublished - Jun 1 2015


  • Dry powder inhaler devices
  • Dry powder inhaler products
  • Inhalable powders
  • Pulmonary drug delivery
  • Solid-state formulation

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Dry powder inhalers in COPD, lung inflammation and pulmonary infections'. Together they form a unique fingerprint.

Cite this